ARDX Ardelyx, Inc.

5.65
-0.35  -6%
Previous Close 6.00
Open 6.05
Price To book 1.70
Market Cap 267.73M
Shares 47,386,000
Volume 629,222
Short Ratio 7.20
Av. Daily Volume 287,061

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due early 4Q 2017. Estimate November 15, 2017 as latest possible date using company guidance of "early 4Q".
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data due 3Q 2017.
RDX7675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. What Do the Ardelyx Numbers Mean for the Company?
  2. Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation
  3. Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
  4. Ardelyx reports 1Q loss
  5. Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
  6. Ardelyx To Present at Upcoming Spring Medical Meetings
  7. Adaptimmune Broadens Executive Team
  8. Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
  9. Wedbush Has A New Best Idea For 2017: Ardelyx
  10. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers
  11. Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
  12. Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
  13. Here’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward
  14. Ardelyx Says Tenapanor Did Well In Phase 3 Study
  15. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  16. Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  17. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  18. Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference